Modality
Degrader
MOA
CFTRmod
Target
PLK4
Pathway
Checkpoint
Myelofibrosis
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
Feb 2020
→ Dec 2027
Phase 1Current
NCT06793345
1,877 pts·Myelofibrosis
2020-02→2027-12·Completed
1,877 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-041.7y awayPh2 Data· Myelofibrosis
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Complet…
Catalysts
Ph2 Data
2027-12-04 · 1.7y away
Myelofibrosis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06793345 | Phase 1/2 | Myelofibrosis | Completed | 1877 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |